Browsing: Bigger

Editor’s Note: This is an excerpt from WBUR’s weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here

The cleanest short thesis on ResMed (NYSE: RMD) is that weight-loss drugs could shrink the obstructive sleep apnea market over time and weaken demand for PAP devices. That framing is too narrow. ResMed is not just selling initial devices into a one-time diagnosis event. It operates a broader sleep-health ecosystem built around installed devices, recurring…